Monopar Therapeutics Posts Earnings Results, Beats Expectations By 0.09 EPS
| MNPR Stock | USD 33.67 1.99 6.28% |
Slightly above 55% of Monopar Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Monopar Therapeutics suggests that some traders are interested. Monopar Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Monopar Therapeutics. Many technical investors use Monopar Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Monopar |
Monopar Therapeutics announced its quarterly earnings data on Friday. The company reported earnings per share for the quarter, beating analysts consensus estimates of by 0.09, reports. Monopar Therapeutics Stock Up 7.3 percent Shares of Monopar Therapeutics stock opened at 16.88 on Monday. The companys fifty day simple
Read at thelincolnianonline.com
 |
Monopar Therapeutics Fundamental Analysis
We analyze Monopar Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Monopar Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Monopar Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Monopar Therapeutics stock to make a market-neutral strategy. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics with similar companies.
Peers
Monopar Therapeutics Related Equities
| PMVP | Pmv Pharmaceuticals | 5.30 | ||||
| ADAG | Adagene | 5.00 | ||||
| RZLT | Rezolute | 3.74 | ||||
| DMAC | DiaMedica Therapeutics | 3.65 | ||||
| CADL | Candel Therapeutics | 3.22 | ||||
| KTTA | Pasithea Therapeutics | 2.89 | ||||
| AVTE | Aerovate Therapeutics | 1.19 | ||||
| MLYS | Mineralys Therapeutics, | 0.69 | ||||
| MOLN | Molecular Partners | 0.57 | ||||
| ANTX | AN2 Therapeutics | 0.79 | ||||
| ACRV | Acrivon Therapeutics, | 0.88 | ||||
| SCPH | Scpharmaceuticals | 0.93 | ||||
| PHVS | Pharvaris | 1.13 | ||||
| PEPG | PepGen | 1.52 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.86 | ||||
| ACXP | Acurx Pharmaceuticals | 4.49 |
Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.